By Christian Torres

Adaptive clinical trials, in which aspects such as medical endpoints and sample sizes can be modified midtrial, are catching on in the pharmaceutical industry to make drug development both faster and cheaper. But as the industry stakes out shortcuts, many researchers are concerned that they might also shortcut the integrity of clinical trials. (Click here to continue reading)